Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-
The present invention provides methods for treating cancer and other pathological proliferating conditions by inhibiting mitosis using at least one pyrrolo[2,3-d]pyrimidine having the general formula (16): where X is selected from the group consisting of lower alkyls, heteroalkyls, substituted or unsubstituted aryls or heteroaryls, arylalkyls, and heteroarylalkyls; where R 1 is selected from the group consisting of hydrogen, lower alkyls, heteroalkyls, substituted or unsubstituted aryls or heteroaryls, arylalkyls, and heteroarylalkyls; where R 2 is selected from the group consisting of hydrogen, lower alkyls, heteroalkyls, alkoxys, substituted or unsubstituted aryls or heteroaryls; where R 3 is selected from the group consisting of zero, lower alkyls, heteroalkyls, alkenyls, and heteroalkenyls; and where R 4 is selected from the group consisting of substituted or unsubstituted aryls or heteroaryls, arylalkyls, heteroarylalkyls, and hydrogen. The compound may inhibit mitosis in cells that have developed multidrug resistance due to P-glycoprotein and MRP1, and facilitate the reversal of P-glycoprotein mediated resistance.
1. A method of treating cancer in a patient in need thereof comprising inhibiting mitosis by administering to the patient an effective amount of at least one compound having the formula (16), wherein the cancer is selected from leukemia or melanoma or a cancer of the lung, colon, brain, ovary, breast, prostate, or kidney:
wherein X is a lower alkyl group;
wherein R 1 is hydrogen;
wherein R 2 is selected from the group consisting of hydrogen, an alkoxy group, and a plurality of alkoxy groups, wherein said alkoxy group or groups has 1-3 carbons;
wherein R 3 is a methylene; and
wherein R 4 is a phenyl group.
2. The method of claim 1 , wherein X is methyl.
3. The method of claim 2 , wherein R 2 is H.
4. The method of claim 1 , wherein said compound is administered by a method selected from the group consisting of parenteral administration, oral administration, and topical administration.
5. The method of claim 1 , wherein said compound is incorporated in a suitable pharmaceutical carrier.
6. The method of claim 5 , wherein said pharmaceutical carrier is selected from the group consisting of physiologic saline and 5 percent dextrose.
7. The method of claim 1 , wherein said compound inhibits polymerization of microtubules and the formation of mitotic spindles.
8. The method of claim 1 , wherein said compound inhibits mitosis in cells that have multidrug resistance.
9. The method of claim 8 , wherein said multidrug resistance is due to P-glycoprotein.
10. The method of claim 8 , wherein said multidrug resistance is due to MRP1.
11. The method of claim 1 , wherein said compound facilitates reversal of multidrug resistance.
12. The method of claim 11 , wherein said multidrug resistance is due to P-glycoprotein.
13. The method of claim 1 , further comprising administering an effective amount of at least one additional chemotherapeutic agent.
14. The method of claim 13 , wherein said additional chemotherapeutic agent is selected from the group consisting of paclitaxel, docetaxel, vinca alkaloids, colchicine, colcemid, cisplatin, and nocadazol.
15. A method of treating cancer in a patient in need thereof comprising:
administering to the patient an effective amount of at least one compound having the formula (16), wherein the cancer is selected from leukemia or melanoma or a cancer of the lung, colon, brain, ovary, breast, prostate, or kidney:
wherein X is a lower alkyl group;
wherein R 1 is hydrogen;
wherein R 2 is selected from the group consisting of hydrogen, an alkoxy group, and a plurality of alkoxy groups, wherein said alkoxy group or groups has 1-3 carbons;
wherein R 3 is a methylene; and
wherein R 4 is a phenyl group; and
administering an effective amount of an additional chemotherapeutic agent.
16. The method of claim 15 , wherein X is methyl.
17. The method of claim 16 , wherein R 2 is H.
18. The method of claim 15 , wherein said additional chemotherapeutic agent is selected from the group consisting of paclitaxel, docetaxel, vinca alkaloids, colchicine, colcemid, cisplatin, and nocadazol.
19. The method of claim 15 , wherein said compound is incorporated in a suitable pharmaceutical carrier.
20. The method of claim 19 , wherein said pharmaceutical carrier is selected from the group consisting of physiologic saline and 5 percent dextrose.
21. The method of claim 15 , wherein said compound is administered by a method selected from the group consisting of parenteral administration, oral administration, and topical administration.
22. The method of claim 15 , wherein said additional chemotherapeutic agent is administered by a method selected from the group consisting of parenteral administration, oral administration, and topical administration.
23. The method of claim 15 , wherein said multidrug resistance is due to P-glycoprotein.
24. The method of claim 15 , wherein said multidrug resistance is due to MRP1.
25. The method of claim 15 , wherein said compound facilitates reversal of P-glycoprotein mediated multidrug resistance.
26. The method of claim 15 , wherein said compound enhances the antimitotic effectiveness of said additional chemotherapeutic agent.
27. The method of claim 15 , wherein said compound and said additional chemotherapeutic agent are administered simultaneously.
28. The method of claim 15 , wherein said compound is administered prior to and separately from said additional chemotherapeutic agent.
29. The method of claim 15 , wherein said compound and said additional chemotherapeutic agent achieve a synergistic effect.